Continuous Glucose Monitoring in Polycystic Ovarian Syndrome
Eligible age
18–45 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to learn more about blood sugar control in polycystic ovarian syndrome. The patient will be asked to wear a continuous glucose monitor (CGM) device that is applied to the arm with a sensor or filament that goes under the skin to measure your sugar levels. The patient will wear this at certain time points throughout the study. There will have a total of 2 blood draws (about 1 tsp. of blood) at screening and the 6-month visit, a measure of the patients body muscle and fat (body composition), and fill out a questionnaire at the end of the first 3 months and 6 months. Study participation in the research will last about 6 months.
Sponsor: The Cleveland Clinic
You may qualify if…
- ✓ 1. Adult 18-45 years old
- ✓ 2. Diagnosis of PCOS by usual clinical method such as by Rotterdam criteria
- ✓ 3. BMI \>25 kg/m2
You may not qualify if…
- ✕ 1. Currently on medications that can improve glucose levels such as metformin and glucagon like receptor 1 agonists (GLP1RA) or on medications taken for the purpose of weight loss such as phentermine, topiramate, and bupropion.
- ✕ 2. Previously intake of above-mentioned medications and less than 3 months since last intake of metformin or weight loss medications, and less than 6 months since last intake of GLP1RA
- ✕ 3. Currently on insulin
- ✕ 4. Does not have Stelo-compatible phone
- ✕ 5. Fasting glucose \>100 mg/dL (because that is the cutoff for prediabetes) (either labs taken within a week after first visit or within 3 months before start of study
- ✕ 6. HbA1c \> 5.7% (because this is the cutoff for prediabetes) (either labs taken after screening visit or within 3 months before start of study)
- ✕ 7. History of anorexia or bulimia
- ✕ 8. Current or previous CGM use
Where it's recruiting
Cleveland
Source: ClinicalTrials.gov · NCT07392476 · last updated 2026-10-06